Genomic analyses identify molecular subtypes of pancreatic cancer P Bailey, DK Chang, K Nones, AL Johns, AM Patch, MC Gingras, ... Nature 531 (7592), 47-52, 2016 | 3207 | 2016 |
Whole genomes redefine the mutational landscape of pancreatic cancer N Waddell, M Pajic, AM Patch, DK Chang, KS Kassahn, P Bailey, ... Nature 518 (7540), 495-501, 2015 | 2638 | 2015 |
EGFR antagonists in cancer treatment F Ciardiello, G Tortora New England Journal of Medicine 358 (11), 1160-1174, 2008 | 2636 | 2008 |
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes AV Biankin, N Waddell, KS Kassahn, MC Gingras, LB Muthuswamy, ... Nature 491 (7424), 399-405, 2012 | 2197 | 2012 |
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ... New England Journal of Medicine 381 (4), 317-327, 2019 | 1976 | 2019 |
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor F Ciardiello, G Tortora Clinical Cancer Research 7 (10), 2958-2970, 2001 | 1430 | 2001 |
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor F Ciardiello, R Caputo, R Bianco, V Damiano, G Pomatico, S De Placido, ... Clinical Cancer Research 6 (5), 2053-2063, 2000 | 1306 | 2000 |
Whole-genome landscape of pancreatic neuroendocrine tumours A Scarpa, DK Chang, K Nones, V Corbo, AM Patch, P Bailey, RT Lawlor, ... Nature 543 (7643), 65-71, 2017 | 858 | 2017 |
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor F Ciardiello, R Caputo, R Bianco, V Damiano, G Fontanini, S Cuccato, ... Clinical cancer research 7 (5), 1459-1465, 2001 | 815 | 2001 |
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases F Carlomagno, D Vitagliano, T Guida, F Ciardiello, G Tortora, G Vecchio, ... Cancer research 62 (24), 7284-7290, 2002 | 714 | 2002 |
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ... Nature genetics 45 (12), 1470-1473, 2013 | 697 | 2013 |
Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA oncology 4 (11), 1543-1552, 2018 | 695 | 2018 |
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial D Goldstein, RH El-Maraghi, P Hammel, V Heinemann, V Kunzmann, ... Journal of the National Cancer Institute 107 (2), dju413, 2015 | 695 | 2015 |
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer G Di Lorenzo, G Tortora, FP D’Armiento, G De Rosa, S Staibano, ... Clinical cancer research 8 (11), 3438-3444, 2002 | 609 | 2002 |
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, ... Annals of Oncology 29 (9), 1895-1902, 2018 | 542 | 2018 |
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in … L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Caliò, ... PloS one 10 (6), e0130142, 2015 | 524 | 2015 |
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense … F Ciardiello, R Bianco, V Damiano, G Fontanini, R Caputo, G Pomatico, ... Clinical Cancer Research 6 (9), 3739-3747, 2000 | 521 | 2000 |
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ... Cancer treatment reviews 41 (2), 114-121, 2015 | 459 | 2015 |
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor … F Ciardiello, R Caputo, V Damiano, R Caputo, T Troiani, D Vitagliano, ... Clinical Cancer Research 9 (4), 1546-1556, 2003 | 459 | 2003 |
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 F Ciardiello, R Bianco, V Damiano, S De Lorenzo, S Pepe, S De Placido, ... Clinical Cancer Research 5 (4), 909-916, 1999 | 436 | 1999 |